+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alzheimer's Therapeutics Market Research Report by Diagnostics, by Therapeutics, by State - United States Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 5367955
  • Report
  • July 2021
  • Region: United States
  • 71 pages
  • 360iResearch™
The United States Alzheimer’s Therapeutics Market is projected to grow with a significant CAGR in the forecast period. Economic development and substantial infrastructure development have constituted regional revenue generation. Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities. Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the United States Alzheimer’s Therapeutics Market.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Alzheimer’s Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Diagnostics, the Alzheimer’s Therapeutics Market was examined across Brain Imaging and CFS Test for Alzheimer's Disease.
  • Based on Drug Class, the Alzheimer’s Therapeutics Market was examined across Cholinesterase Inhibitors and NMDA [N-methyl-D-aspartate] Receptor Antagonist.
  • Based on Therapeutics, the Alzheimer’s Therapeutics Market was examined across Cholinesterase Inhibitors and NMDA Receptor Antagonists.
  • Based on Geography, the Alzheimer’s Therapeutics Market was examined across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.
Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Alzheimer’s Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Alzheimer’s Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Alzheimer’s Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Alzheimer’s Therapeutics Market?
4. What is the competitive strategic window for opportunities in the United States Alzheimer’s Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the United States Alzheimer’s Therapeutics Market?
6. What is the market share of the leading vendors in the United States Alzheimer’s Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the United States Alzheimer’s Therapeutics Market?
Note: Product cover images may vary from those shown
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Diagnostics Outlook
3.4. Drug Class Outlook
3.5. Therapeutics Outlook
3.6. Geography Outlook
3.7. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges

6. Alzheimer’s Therapeutics Market, by Diagnostics
6.1. Introduction
6.2. Brain Imaging
6.3. CFS Test for Alzheimer's Disease

7. Alzheimer’s Therapeutics Market, by Drug Class
7.1. Introduction
7.2. Cholinesterase Inhibitors
7.3. NMDA [N-methyl-D-aspartate] Receptor Antagonist

8. Alzheimer’s Therapeutics Market, by Therapeutics
8.1. Introduction
8.2. Cholinesterase Inhibitors
8.3. NMDA Receptor Antagonists

9. Competitive Landscape
9.1. FPNV Positioning Matrix
9.1.1. Quadrants
9.1.2. Business Strategy
9.1.3. Product Satisfaction
9.2. Market Ranking Analysis
9.3. Market Share Analysis, By Key Player
9.4. Competitive Scenario
9.4.1. Merger & Acquisition
9.4.2. Agreement, Collaboration, & Partnership
9.4.3. New Product Launch & Enhancement
9.4.4. Investment & Funding
9.4.5. Award, Recognition, & Expansion

10. Company Usability Profiles

11. Appendix
11.1. Discussion Guide
11.2. License & Pricing

List of Figures
Figure 1. United States Alzheimer's Therapeutics Market Size, 2020 Vs 2026 (USD Million)
Figure 2. United States Alzheimer's Therapeutics Market Size, by Diagnostics, 2020 (USD Million)
Figure 3. United States Alzheimer's Therapeutics Market Size, by Drug Class, 2020 (USD Million)
Figure 4. United States Alzheimer's Therapeutics Market Size, by Therapeutics, 2020 (USD Million)
Figure 5. United States Alzheimer's Therapeutics Market Size, by Geography, 2020 Vs 2026 (USD Million)
Figure 6. United States Alzheimer's Therapeutics Market Size, 2018-2026 (USD Million)
Figure 7. United States Alzheimer's Therapeutics Market: Market Dynamics
Figure 8. United States Alzheimer's Therapeutics Market Size, by Diagnostics, 2020 Vs 2026 (%)
Figure 9. United States Alzheimer's Therapeutics Market Size, by Diagnostics, 2020 Vs 2026 (USD Million)
Figure 10. Competitive Strategic Window for United States Alzheimer's Therapeutics Market Size, by Diagnostics, 2026
Figure 11. United States Alzheimer's Therapeutics Market Size, by Brain Imaging, 2018-2026 (USD Million)
Figure 12. United States Alzheimer's Therapeutics Market Size, by Brain Imaging, by Geography, 2020 Vs 2026 (USD Million)
Figure 13. United States Alzheimer's Therapeutics Market Size, by Cfs Test for Alzheimer's Disease, 2018-2026 (USD Million)
Figure 14. United States Alzheimer's Therapeutics Market Size, by Cfs Test for Alzheimer's Disease, by Geography, 2020 Vs 2026 (USD Million)
Figure 15. United States Alzheimer's Therapeutics Market Size, by Drug Class, 2020 Vs 2026 (%)
Figure 16. United States Alzheimer's Therapeutics Market Size, by Drug Class, 2020 Vs 2026 (USD Million)
Figure 17. Competitive Strategic Window for United States Alzheimer's Therapeutics Market Size, by Drug Class, 2026
Figure 18. United States Alzheimer's Therapeutics Market Size, by Cholinesterase Inhibitors, 2018-2026 (USD Million)
Figure 19. United States Alzheimer's Therapeutics Market Size, by Cholinesterase Inhibitors, by Geography, 2020 Vs 2026 (USD Million)
Figure 20. United States Alzheimer's Therapeutics Market Size, by Nmda [N-Methyl-D-Aspartate] Receptor Antagonist, 2018-2026 (USD Million)
Figure 21. United States Alzheimer's Therapeutics Market Size, by Nmda [N-Methyl-D-Aspartate] Receptor Antagonist, by Geography, 2020 Vs 2026 (USD Million)
Figure 22. United States Alzheimer's Therapeutics Market Size, by Therapeutics, 2020 Vs 2026 (%)
Figure 23. United States Alzheimer's Therapeutics Market Size, by Therapeutics, 2020 Vs 2026 (USD Million)
Figure 24. Competitive Strategic Window for United States Alzheimer's Therapeutics Market Size, by Therapeutics, 2026
Figure 25. United States Alzheimer's Therapeutics Market Size, by Cholinesterase Inhibitors, 2018-2026 (USD Million)
Figure 26. United States Alzheimer's Therapeutics Market Size, by Cholinesterase Inhibitors, by Geography, 2020 Vs 2026 (USD Million)
Figure 27. United States Alzheimer's Therapeutics Market Size, by Nmda Receptor Antagonists, 2018-2026 (USD Million)
Figure 28. United States Alzheimer's Therapeutics Market Size, by Nmda Receptor Antagonists, by Geography, 2020 Vs 2026 (USD Million)
Figure 29. United States Alzheimer's Therapeutics Market: Fpnv Positioning Matrix
Figure 30. United States Alzheimer's Therapeutics Market: Share, by Key Player, 2020
Figure 31. Competitive Scenario Analysis in United States Alzheimer's Therapeutics Market, by Type

List of Tables
Table 1. United States Alzheimer's Therapeutics Market: Market Segmentation & Coverage
Table 2. United States Dollar Exchange Rate, 2016-2020
Table 3. United States Alzheimer's Therapeutics Market Size, 2018-2026 (USD Million)
Table 4. United States Alzheimer's Therapeutics Market Size, by Diagnostics, 2018-2026 (USD Million)
Table 5. United States Alzheimer's Therapeutics Market Size, by Brain Imaging, by Geography, 2018-2026 (USD Million)
Table 6. United States Alzheimer's Therapeutics Market Size, by Cfs Test for Alzheimer's Disease, by Geography, 2018-2026 (USD Million)
Table 7. United States Alzheimer's Therapeutics Market Size, by Drug Class, 2018-2026 (USD Million)
Table 8. United States Alzheimer's Therapeutics Market Size, by Cholinesterase Inhibitors, by Geography, 2018-2026 (USD Million)
Table 9. United States Alzheimer's Therapeutics Market Size, by Nmda [N-Methyl-D-Aspartate] Receptor Antagonist, by Geography, 2018-2026 (USD Million)
Table 10. United States Alzheimer's Therapeutics Market Size, by Therapeutics, 2018-2026 (USD Million)
Table 11. United States Alzheimer's Therapeutics Market Size, by Cholinesterase Inhibitors, by Geography, 2018-2026 (USD Million)
Table 12. United States Alzheimer's Therapeutics Market Size, by Nmda Receptor Antagonists, by Geography, 2018-2026 (USD Million)
Table 13. United States Alzheimer's Therapeutics Market: Scores
Table 14. United States Alzheimer's Therapeutics Market: Business Strategy
Table 15. United States Alzheimer's Therapeutics Market: Product Satisfaction
Table 16. United States Alzheimer's Therapeutics Market: Ranking
Table 17. United States Alzheimer's Therapeutics Market: Share, by Key Player, 2020
Table 18. United States Alzheimer's Therapeutics Market: Merger & Acquisition
Table 19. United States Alzheimer's Therapeutics Market: Agreement, Collaboration, & Partnership
Table 20. United States Alzheimer's Therapeutics Market: New Product Launch & Enhancement
Table 21. United States Alzheimer's Therapeutics Market: Investment & Funding
Table 22. United States Alzheimer's Therapeutics Market: Award, Recognition, & Expansion
Table 23. United States Alzheimer's Therapeutics Market: License & Pricing
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll